Analisi costo/efficacia della doxofillina vs. teofillina nella terapia dell’asma cronica reversibile dell’adulto. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 3, n. 2, p. 103–117, 2002. DOI: 10.7175/fe.v3i2.748. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/748. Acesso em: 29 oct. 2025.